Ascendis Pharma's TransCon CNP Wins Positive CHMP Opinion for Childhood Achondroplasia
CHMP recommends EU authorization of Ascendis Pharma’s once-weekly TransCon CNP for achondroplasia in children aged two or older with open epiphyses. A final European Commission decision is expected in the fourth quarter of 2026. If authorized, the first EU launch is planned in Germany in the first quarter of 2027 under